| Date | Form | Description | Docs | XBRL | Pages |
| 04/11/18 | 144 | Filing for proposed sale of securities under Rule 144 |
|
2 | |
| 04/02/18 | 8-K | Current report filing |
|
4 | |
| 03/27/18 | 8-K | Current report filing |
|
48 | |
| 03/27/18 | 424B5 | Prospectus filed pursuant to Rule 424(b)(5) |
|
35 | |
| 03/09/18 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) |
|
|
31 |
| 03/05/18 | 8-K | Current report filing |
|
4 | |
| 02/15/18 | CT ORDER | Confidential treatment order |
|
1 | |
| 02/15/18 | SC 13D | Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities |
|
6 | |
| 02/14/18 | S-8 | Initial registration statement for securities to be offered to employees pursuant to employee benefit plans |
|
37 | |
| 02/12/18 | DEF 14A | Definitive proxy statements |
|
36 |
Latest News & Events
Anixa Biosciences Announces Dr. Jose Conejo-Garcia will Keynote the South Carolina Clinical & Translational Research Institute 2026 Retreat
Read More...Anixa Biosciences Reports Encouraging Patient Survival Observations in Ovarian Cancer CAR-T Trial; Achieves Regulatory Approval Enabling Major Dose Escalation
Read More...Anixa Biosciences Secures United States Adopted Names Council Approval of Non-Proprietary Name for its CAR-T Therapy, a Key Step Toward Future Commercialization
Read More...